English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

An observational study was set up to assess the feasibility of [ 18 F]FPRGD 2  PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined [ 18 F]NaF/[ 18 F]FDG PET/CT images. Four patients (2 newly diagnosed patients and 2 with relapsed MM) were included and underwent whole-body PET/CT after injection of [ 18 F]FPRGD 2 . The obtained images were compared with results of low dose CT and already available results of a combined [ 18 F]NaF/[ 18 F]FDG PET/CT. In total, 81 focal lesions (FLs) were detected with PET/CT and an underlying bone destruction or fracture was seen in 72 (89%) or 8 (10%) FLs, respectively. Fewer FLs (54%) were detected by [ 18 F]FPRGD 2  PET/CT compared to low dose CT (98%) or [ 18 F]NaF/[ 18 F]FDG PET/CT (70%) and all FLs detected with [ 18 F]FPRGD 2  PET were associated with an underlying bone lesion. In one newly diagnosed patient, more [ 18 F]FPRGD 2  positive lesions were seen than [ 18 F]NaF/[ 18 F]FDG positive lesions. This study suggests that [ 18 F]FPRGD 2  PET/CT might be less useful for the detection of myeloma lesions in patients with advanced disease as all FLs with [ 18 F]FPRGD 2  uptake were already detected with CT alone.

A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma

A First Report on [¹⁸F]FPRGD₂ PET/CT Imaging in Multiple Myeloma